// App-Quantinova.ai

PO‐069 : Preliminary results of a phase 1b dose escalation and dose expansion study of GS‐4059 in combination with idelalisib in subjects with B‐cell malignancies

Researchers

Presenter

  • MJS Dyer

Principal Investigators

  • F Morschhauser

  • B Cheson

  • SA Rule

  • C Fegan

  • G Cartron

  • C Nelson

  • Y Yang

  • S Mitra

  • A Starodub

  • G Salles

Medical Centers

  • The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • Department of Clinical Hematology, Centre Hospitalier Regional Universitaire (CHRU) de Lille, and Unite Groupe de Recherche sur les Formes Injetables et les Technologies Associees (GRITA), Universite de Lille 2, Lille, France

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, United Kingdom

  • Cardiff CLL Research Group, School of Medicine, Heath Park, Cardiff University, Cardiff, Wales, United Kingdom

  • Department of Clinical Hematology and Unite Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), CHRU, Montpellier, France

  • Gilead Sciences, Inc., Foster City, CA

  • Indiana University Health Goshen Hospital, Goshen, IN

  • Hospices Civils de Lyon, Centre Hospitalier Lyon Sud - Service dEndocrinologie, Pierre Benite, France

Locations

  • United Kingdom

  • France

  • United States

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Alanine transaminase

  • Bruton tyrosine kinase

Drug/Treatment

  • Alkaline phosphatase

  • Phosphatidylinositol

  • Idelalisib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Fixed Dose

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02457598

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved